Oral tolerance induction by collagen to prevent allograft rejection
CA 2402489 C · Owner: Wilkes, David S. · Inventors: Wilkes, David S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of collagen and MHC-like compounds to down regulate immune responses. Methods for administration of such compounds that induce immune tolerance are described. The invention is important in the context of allograft rejection, transplantation graft rejection, pleural , disease and immunotolerance.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 15, 2001 and granted November 1, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 15, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 15, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.